144 ·Filed Jun 18, 2026

MRNA

Moderna, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed3mo ago SEC0001959173-26-004772
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

The filing is a routine advance notice of a small sale by a former director. Monitor whether the sale actually executes, but no material read-through for MRNA stock. The insider's status as a former director reduces signaling significance.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
MRNA ▲ +129.35% at T+60d
NEUTRAL call ✓ call won +129.35% · α vs SPY +127.45% · entry $63.96 → $146.69
Entry anchored
Jun 18, 03:26 PM ET
via exchange tick
T+1d
-7.22%
call -7.22% · α -6.90%
$59.35
settled 3mo ago
T+5d
-6.58%
call -6.58% · α -4.92%
$59.75
settled 3mo ago
T+20d
-1.27%
call -1.27% · α -1.80%
$63.15
settled 2mo ago
T+60d
+129.35%
call +129.35% · α +127.45%
$146.69
settled 17d ago

Price Chart

Loading chart...

Executive Summary

Former director Paul Sagan filed a Form 144 notice of intent to sell 25,770 shares of Moderna common stock, valued at approximately $1.66 million, acquired via stock option exercise. The proposed sale is small relative to Moderna's $24.5B market cap and represents a routine insider transaction with limited signaling value.

Key Facts

  • Former director Paul Sagan filed Form 144 to sell 25,770 shares of MRNA common stock.
  • Estimated market value of proposed sale: $1,663,874.56.
  • Shares were acquired through a stock option exercise on the same date (06/18/2026).
  • Sale represents ~0.007% of Moderna's $24.5B market cap.
  • Only one other insider sale ($2.7M) was reported in the prior 30 days.

Financial Impact

Proposed sale of ~$1.66M, negligible relative to $24.5B market cap.

dilution

Risk Factors

  • No material risks identified from this filing alone.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
13% bullish (30 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-004772
Document: 0001959173-26-004772-index.html0001959173-26-004772
Document: 0001959173-26-004772.txt0001959173-26-004772
18 reports for MRNA
Performance horizon
80% Hit rate 4 of 5 directional calls best @ T+60▲ +14.15%Mar 5, 2026
Filters
Rows
Reports for MRNA — sortable, filterable
TypeNow
Sep 30, 2026
2d ago
ANALYST-DOWNGRADE
BEARISH ★ 4/10
—awaiting T+5——
Sep 3, 2026
29d ago
ANALYST-DOWNGRADE
BEARISH ★ 6/10
$148.87 $143.97▲ +3.29%▲ +2.14%$190.01 (−27.63%)
Aug 31, 2026
4w ago
Court Ruling
BEARISH ★ 6/10
$140.19 $140.33▼ −0.10%▼ −0.24%$190.01 (−35.54%)
Aug 25, 2026
5w ago
ANALYST-UPGRADE
MIXED ★ 1/10
$158.83 $154.27▼ −2.87%▼ −2.33%$190.01 (+19.63%)
Aug 19, 2026
6w ago
ANALYST-UPGRADE
MIXED ★ 1/10
$174.38 $149.66▼ −14.18%▼ −13.79%$190.01 (+8.96%)
Aug 5, 2026
8w ago
144
BEARISH ★ 6/10
$56.26 $63.67▼ −13.18%▼ −12.83%$190.01 (−237.77%)
Jul 31, 2026
9w ago
8-K
MIXED ★ 6/10
$54.82 $59.17▲ +7.94%▲ +4.42%$190.01 (+246.61%)
Jul 10, 2026
11w ago
3
NEUTRAL ★ 2/10
$67.01 $61.82▼ −7.75%▼ −6.96%$190.01 (+183.55%)
Jul 8, 2026
12w ago
8-K
NEUTRAL ★ 2/10
$73.80 $67.44▼ −8.62%▼ −9.48%$190.01 (+157.47%)
Jun 18, 2026
15w ago
144
NEUTRAL ★ 2/10
$63.96 $59.75▼ −6.58%▼ −4.92%$190.01 (+197.08%)
Showing 10 of 18

US Market Status

Market Closed — Opens Mon (65h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access